Gallop Oncology
LYT-200
relapsed/refractory high-risk myelodysplastic syndrome
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews LYT-200 for relapsed/refractory high-risk myelodysplastic syndrome around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 12h ago
“Gallop has selected a recommended Phase 2 dose and intends to engage with the FDA to discuss the design of a subsequent trial in 2025.”